JACC Basic to Translational Science · 2019 · 120 citations · 25 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyMolecular PharmacologyCardiac MedicationsCardiac PharmacotherapyDiabetes PharmacotherapyHeart FailureHemodynamic PharmacologySodium-glucose Cotransporter 2 InhibitorsCell Wall Stress ResponsesHeart Failure PharmacologyLeft Ventricular Diastolic DysfunctionSodium-glucose CotransportSodium-glucose Cotransporter 2 InhibitionSystolic DysfunctionType 2 Diabetes PathophysiologyVentricular Diastolic Function
Recent studies send an unambiguous signal that the class of agents known as sodium-glucose-linked co-transporter-2 inhibitors (SGLT2i) prevent heart failure hospitalization in patients with type 2 diabetes. However, the mechanisms remain unclear. Herein the authors utilize a rodent model of heart failure with preserved ejection fraction (HFpEF), and demonstrate that treatment with the SGLT2i empagliflozin, reduces left ventricular mass, improving both wall stress and diastolic function. These findings extend the observation that the main mechanism of action of empagliflozin involves improved hemodynamics (i.e., reduction in preload and afterload) and provide a rationale for upcoming trials in patients with HFpEF irrespective of glycemic status.
25
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
Marlies Antlanger, Stefan Aschauer, Chantal Kopecky et al. · Kidney & Blood Pressure Research · 2017 · 2.8K citations · Full text